Adverum Biotechnologies, Inc. (65)
Browse by Contract Category
Contracts
-
Amended and Restated
(Filed With SEC on August 11, 2022)
-
Consulting Agreement between Adverum Biotechnologies, Inc. and Nancy E. Pecota, dated as of June 29, 2022
(Filed With SEC on August 11, 2022)
-
Sublease Agreement between Adverum NC, LLC and Jaguar Gene Therapy, LLC, dated as of October 26, 2021
(Filed With SEC on March 29, 2022)
-
Description of Common Stock
(Filed With SEC on March 1, 2021)
-
Form of Indemnification Agreement for Directors and Executive Officers
(Filed With SEC on May 28, 2020)
-
License Agreement, between the Company and Virovek, Inc. (Virovek), dated October 12, 2011 (the Virovek License)
(Filed With SEC on March 6, 2019)
-
Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of June 7, 2022
(Filed With SEC on August 11, 2022)
-
Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of June 4, 2022
(Filed With SEC on August 11, 2022)
-
Promotion Letter between Adverum Biotechnologies, Inc. and John Rakow, dated as of July 1
(Filed With SEC on August 11, 2022)
-
Employment Agreement between Adverum Biotechnologies, Inc. and John Rakow, dated as of January 2
(Filed With SEC on August 11, 2022)
-
Employment Agreement
(Filed With SEC on March 29, 2022)
-
Employment Agreement
(Filed With SEC on March 29, 2022)
-
Employment Agreement between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of November 12, 2021
(Filed With SEC on March 29, 2022)
-
Employment Agreement between Adverum Biotechnologies, Inc. and Brigit Riley, dated as of May 21, 2021
(Filed With SEC on March 29, 2022)
-
Form of Change in Control
(Filed With SEC on March 29, 2022)
-
Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2014 Equity Incentive Award Plan
(Filed With SEC on March 29, 2022)
-
Sublease Agreement between Adverum Biotechnologies, Inc. and Revolution Medicines, Inc., dated as of November 1, 2021
(Filed With SEC on March 29, 2022)
-
Second Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of November 1, 2021
(Filed With SEC on March 29, 2022)
-
Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Angela Thedinga, dated October 1, 2021
(Filed With SEC on November 4, 2021)
-
Consulting Agreement between Adverum Biotechnologies, Inc. and Angela Thedinga, dated October 1, 2021
(Filed With SEC on November 4, 2021)
-
Change in Control and Severance Agreement with Chris DeRespino, dated February 1, 2021
(Filed With SEC on August 5, 2021)
-
Employment Offer Letter with Chris DeRespino, dated February 1, 2021
(Filed With SEC on August 5, 2021)
-
Change in Control and Severance Agreement with Julie Clark, dated May 25, 2021
(Filed With SEC on August 5, 2021)
-
Promotion Letter with Julie Clark, dated May 22, 2021
(Filed With SEC on August 5, 2021)
-
Employment Offer Letter with Julie Clark, dated April 2, 2020
(Filed With SEC on August 5, 2021)
-
Consulting Agreement between Adverum Biotechnologies, Inc. and Leone Patterson, dated June 24, 2021
(Filed With SEC on August 5, 2021)
-
First Lease Amendment by and between HCP LS Redwood City, LLC and Adverum Biotechnologies, Inc., dated
(Filed With SEC on August 5, 2021)
-
Non-Employee Director Compensation Policy, effective May 5, 2021
(Filed With SEC on May 6, 2021)
-
Non-Employee Director Compensation Policy, effective March 31, 2021
(Filed With SEC on May 6, 2021)
-
Lease Agreement and Letter Agreement by and between Adverum NC, LLC (a wholly owned subsidiary of Adverum Biotechnologies, Inc.) and ARE-NC REGION NO. 21, LLC, dated January 8,...
(Filed With SEC on May 6, 2021)
-
Consulting Agreement between Adverum Biotechnologies, Inc. and Thomas Leung, dated February 2, 2021
(Filed With SEC on May 6, 2021)
-
Separation Agreement between Adverum Biotechnologies, Inc. and Thomas Leung, dated February 2, 2021
(Filed With SEC on May 6, 2021)
-
Consulting Agreement between Adverum Biotechnologies, Inc. and Aaron Osborne, dated March 18, 2021
(Filed With SEC on May 6, 2021)
-
Separation Agreement between Adverum Biotechnologies, Inc. and Aaron Osborne, dated April 7, 2021
(Filed With SEC on May 6, 2021)
-
Common Stock Sales Agreement, dated December 17, 2020
(Filed With SEC on December 17, 2020)
-
Underwriting Agreement, dated August 12, 2020
(Filed With SEC on August 13, 2020)
-
Adverum Biotechnologies, Inc. Amended and Restated 2017 Inducement Plan
(Filed With SEC on August 10, 2020)
-
Adverum Biotechnologies, Inc. Amended and Restated 2014 Equity Incentive Plan
(Filed With SEC on August 10, 2020)
-
Adverum Biotechnologies, Inc. Amended and Restated 2006 Equity Incentive Plan
(Filed With SEC on August 10, 2020)
-
Amended and Restated Non-Employee Director Compensation Policy, effective June 22, 2020
(Filed With SEC on August 10, 2020)
-
Amended and Restated Change in Control and Severance Agreement with Leone Patterson, dated
(Filed With SEC on August 10, 2020)
-
Amended and Restated Change in Control and Severance Agreement with Leone Patterson, dated
(Filed With SEC on August 10, 2020)
-
Amended and Restated Offer Letter with Leone Patterson, dated
(Filed With SEC on August 10, 2020)
-
Change in Control and Severance Agreement Laurent Fischer, dated
(Filed With SEC on August 10, 2020)
-
Employment Offer Letter with Laurent Fischer, dated
(Filed With SEC on August 10, 2020)
-
Promotion Letter, dated February 21, 2020, between Adverum Biotechnologies, Inc. and Angela Thedinga
(Filed With SEC on May 28, 2020)
-
Employment Agreement, dated
(Filed With SEC on May 28, 2020)
-
Description of Common Stock
(Filed With SEC on March 12, 2020)
-
Non-Employee Director Compensation Policy, effective December 13, 2019
(Filed With SEC on March 12, 2020)
-
Underwriting Agreement, dated February 11, 2020
(Filed With SEC on February 12, 2020)
-
Non-Employee Director Compensation Policy, effective August 15, 2019
(Filed With SEC on November 7, 2019)
-
Separation Letter and Consulting Agreement, dated September 3, 2019 and September 6, 2019, respectively, between Adverum Biotechnologies, Inc. and Jennifer Cheng
(Filed With SEC on November 7, 2019)
-
Separation and Consulting Agreement, dated July 31, 2019, between Adverum Biotechnologies, Inc. and Mehdi Gasmi
(Filed With SEC on November 7, 2019)
-
Employment Agreement, dated October 11, 2019, among Adverum Biotechnologies, Inc. and Peter Soparkar
(Filed With SEC on November 7, 2019)
-
Employment Agreement, dated February 28, 2019, among Adverum Biotechnologies, Inc. and Aaron Osborne
(Filed With SEC on November 7, 2019)
-
Separation Letter, dated May 1, 2019, between Adverum Biotechnologies, Inc. and Paul Cleveland
(Filed With SEC on August 8, 2019)
-
Employment Agreement, dated February 27, 2019, with Thomas Leung
(Filed With SEC on May 8, 2019)
-
Cooperation Agreement, dated as of May 1, 2019, among Adverum Biotechnologies, Inc., The Sonic Fund II, L.P. and Lawrence Kam
(Filed With SEC on May 2, 2019)
-
2017 Inducement Plan, as amended and restated
(Filed With SEC on March 6, 2019)
-
Exclusive License Agreement, between the Company and the Regents of the University of California (UC), dated June 17, 2013 (the UC License)
(Filed With SEC on March 6, 2019)
-
Amendment to the Change in Control and Severance Agreement for Mehdi Gasmi
(Filed With SEC on March 6, 2019)
-
Amended and Restated Offer Letter with Leone Patterson, dated October 24, 2018
(Filed With SEC on March 6, 2019)
-
Change in Control and Severance Agreement with Leone Patterson, dated October 24, 2018
(Filed With SEC on March 6, 2019)
-
Adverum Biotechnologies, Inc. 2014 Equity Incentive Award Plan, as amended and restated
(Filed With SEC on March 6, 2019)
-
Adverum Biotechnologies, Inc. 2014 Employee Stock Purchase Plan, as amended and restated
(Filed With SEC on March 6, 2019)